Printer Friendly

Cosentyx Reduces Structural Joint Damage in Psoriatic Arthritis Compared to Placebo.

M2 PHARMA-November 8, 2017-Cosentyx Reduces Structural Joint Damage in Psoriatic Arthritis Compared to Placebo

(C)2017 M2 COMMUNICATIONS

- East Hanover, New Jersey-based healthcare solutions provider Novartis Pharmaceuticals Corp. has released results from the FUTURE 5 study showing Cosentyx (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression of joint structural damage in PsA patients compared to placebo at 24 weeks, the company said.

The Phase III study participants (n=996) were randomised to receive Cosentyx, 300 mg with loading dosage, 150 mg with LD, 150 mg without LD, or placebo.

At week 24, more participants treated with Cosentyx had no worsening of joint structural damage compared to placebo, as measured by the modified total van der Heijde Sharp score (mTSS), a detailed scoring method evaluating erosion in the joints.

Participants taking Cosentyx achieved significant improvements in the signs and symptoms of PsA compared to placebo at 16 weeks, as measured by the ACR, a standard tool used to assess improvement of PsA signs and symptoms such as tender and swollen joints, pain and physical functioning.

The safety profile was consistent with that observed in previous studies and similar across arms, with no new adverse events identified. The most common adverse events at week 16 were upper respiratory tract infection, headache, hypertension, and urinary tract infection.

Cosentyx, a fully human monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor, is the only IL-17a approved for the treatment of active ankylosing spondylitis and PsA.

Novartis Pharmaceuticals is an affiliate of Novartis which provides innovative healthcare solutions that address the evolving needs of patients and societies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 8, 2017
Words:289
Previous Article:Ionis Submits NDA for Inotersen to the US FDA.
Next Article:Promising results from malaria breath test clinical trial.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters